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The early history of infectious diseases was characterized by sudden, unpredictable
outbreaks, frequently of epidemic proportion. Scientific advances in the late 19th and
early 20th centuries resulted in the prevention and control of many infectious diseases,
particularly in industrialized nations. Despite these improvements in health, out-
breaks of infectious disease continue to occur, and new infections emerge. Since 1987,
the National Academy of Science’s Institute of Medicine (IOM) has published three
reports that have identified erosion of the public health infrastructure among the
factors contributing to new and reemerging infectious diseases. In partnership with
many public and private organizations in the United States and abroad, the Centers
for Disease Control and Prevention (CDC) has developed a strategic plan that
addresses the priorities set forth in the IOM reports and serves as a guide for CDC
and its partners to combat emerging microbial threats to health. Laboratory-based
surveillance, better communication networks, and improvements in the public health
infrastructure are the cornerstones of the strategy. Emerging Infectious Diseases, a
new periodical produced by CDC, will serve as a forum for exchange of information
about incipient trends in infectious diseases, analysis of factors contributing to disease
emergence, and development and implementation of prevention measures.
“Nothing in the world of living things is permanently fixed.” 
Hans Zinnser—Rats, Lice and History, 1935
Early History of Infectious Diseases
Infectious diseases have plagued humans since
the dawn of civilization (1-5). The history of these
diseases provides a valuable perspective for evalu-
ating current trends. Humans are presumed to have
originated in tropical climates and to have been
affected by the same parasitic diseases as other
primates in these areas. As available supplies of
game diminished, early hunters migrated into tem-
perate zones which were free of tropical parasites.
Historians speculate that humans were relatively
safe from infectious diseases during that period.
Later, however, as agriculture began to provide a
substantial portion of the human diet, populations
stabilized and grew. Eventually, populations
reached a size that would support persistent person-
to-person spread of infectious microorganisms. With
this newly established mode of transmission, infec-
tious diseases soon became widespread. The exact
origins of many infectious agents remain obscure,
but with the advent of large populations, humans
eventually became the established reservoir of many
agents. Infected animals and contaminated food and
water were additional sources of infectious microor-
ganisms.
Dissemination of infectious diseases intensified
as civilizations progressed. Caravans of traders car-
ried new pathogens to unsuspecting and susceptible
populations. Explorers and later conquering armies
brought infectious microorganisms to new conti-
nents. Stowaway rats and other vermin in the holds
of ships traveled down the moorings when the ships
docked, bringing fleas, lice, and deadly pathogens to
a new world. Sporadic epidemics of plague, small-
pox, typhus, and measles ravaged cities, decimated
armies, and altered the course of history.
19th Century Discoveries Lead to
Infectious Disease Prevention and Control
Control of many infectious diseases became pos-
sible with the pioneering work of Robert Koch and
Louis Pasteur and the introduction of the germ
theory of disease. With bacteriologic cultivation
techniques came the first isolation and identifica-
tion of etiologic agents; virus cultivation and identi-
fication became available some decades later.
Reservoirs of microorganisms and their life cycles
were identified; the epidemiology and natural his-
tory of many infectious diseases were described, and
successful control measures were initiated. Water
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grams followed. By the beginning of the 20th cen-
tury, the principles of vaccination, established
empirically by Edward Jenner more than 100 years
earlier, began to be realized in earnest. Antibiotics
were discovered, and disinfectants were developed.
Collectively, these control measures dramatically
decreased the incidence and prevalence of many
infectious diseases and their fatality rates. The early
part of this century is appropriately regarded as a
golden age in public health.
New and Reemerging Infectious
Diseases—A Contemporary Problem
Compared with earlier generations, we possess
an enormous scientific base, and the rate of acquisi-
tion of new information about infectious diseases is
at a historic high. Moreover, thanks in large measure
to effective childhood immunization programs, in-
cluding the President’s Childhood Immunization In-
itiative, many infectious diseases are under control,
particularly in the industrialized world. The elimi-
nation of smallpox in 1977 stands as a towering
achievement in the fight against infectious diseases.
However, many infectious diseases have persisted
and have displayed a remarkable ability to re-
emerge after lengthy periods of stability. Therefore,
we must be ever mindful of the cyclical nature of
disease trends. 
A careful review of infectious disease trends
shows a fragile equilibrium between humans and
infectious microorganisms. Infectious diseases are
still broadly endemic and maintain a large reservoir
of agents that have the potential for rapid and wide-
spread dissemination. Infectious diseases remain
the leading cause of death worldwide, even as the
International Code of Diseases places many infec-
tious diseases in other categories. For example, men-
ingitis and cirrhosis are classified as diseases of the
nervous system and liver, respectively, and only 17%
of deaths attributable to infections are actually in-
cluded in the codes for parasitic and infectious dis-
eases (6). In the United States, each year,
approximately 25% of physician visits are attribut-
able to infectious diseases, with direct and indirect
costs, including those for human immunodeficiency
virus (HIV) infection and related illnesses, esti-
mated at more than $120 billion (7).
Persons living in tropical climates are still as
vulnerable to infectious diseases as their early an-
cestors were. Each year more than one million chil-
dren die of malaria in sub-Saharan Africa alone (8);
worldwide, approximately 200 million people have
schistosomiasis (9), and each year 35-60 million peo-
ple contract dengue (10). Moreover, infectious dis-
eases and their attendant problems are not confined
to tropical climates. For example,  an estimated
600,000 cases of pneumonia occur in the United
States each year and cause 25,000 to 50,000 deaths
(11). More than 10,000 cases of diphtheria have
occurred in Russia since 1993 because of inadequate
levels of immunization (12). Despite a century of
scientific progress, infectious diseases still cause
enormous human suffering, deplete scarce re-
sources, impede social and economic development,
and contribute to global instability. The potential for
even greater dissemination looms as a continuous
threat.
Recent outbreaks underscore the potential for the
sudden appearance of infectious diseases in cur-
rently unaffected populations. In the United States,
contamination of the municipal water supply in Mil-
waukee, Wisconsin, in 1993 resulted in an outbreak
of cryptosporidiosis that affected an estimated
400,000 people; approximately 4,400 persons re-
quired hospitalization (13). In the 1990s, epidemic
cholera reappeared in the Americas, after being ab-
sent for nearly a century; from 1991 through June
of 1994 more than one million cases and nearly
10,000 deaths were reported (14). During the 1980s,
tuberculosis reemerged in the United States after
decades of decline, and drug-resistant strains have
made its control more difficult (15,16). The increas-
ing prevalence of antibiotic-resistant strains of
gonococci, pneumococci, enterococci, and staphylo-
cocci portend of other serious treatment and control
failures. Many other examples of emerging infec-
tions could be given (17,18). 
New infectious diseases, often with unknown
long-term public health impact, continue to be iden-
tified. Table 1 lists major diseases or etiologic agents
identified just within the last 20 years (19-41). New
agents are regularly added to the list, particularly
with the availability of nucleic acid amplification
techniques for detecting and identifying otherwise
noncultivable microorganisms (40, 42).
In some cases, etiologic agents have been identi-
fied as the causes of known diseases or syndromes
(e.g., rotavirus, parvovirus, human T-cell lympho-
tropic viruses I and II (HTLV I/II), and human her-
pesvirus type 6, (HHV-6); in other cases, diseases
became better recognized or defined (e.g., Legion-
naires’ disease, Lyme disease, human ehrlichiosis).
Still others are entirely new: with some parallels to
medieval times, a previously unknown and deadly
disease, acquired immunodeficiency syndrome
(AIDS), originated from uncertain sources in one
part of the world and became globally disseminated;
this time the disease spread at a rate that would
have been unthinkable in medieval times. Clearly,
the complete history of infectious diseases remains
to be written.
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Recent disquieting infectious disease trends have
not gone unrecognized, and their similarity to earlier
disease trends with immense global consequences
has not gone unnoticed. Primary responsibility for
addressing new and reemerging infectious diseases
rests squarely with the custodians of public health.
Indeed, the fundamental maxim of public health
must guide current prevention programs: the health
of the individual is best ensured by maintaining or
improving the health of the entire community. Core
functions necessary to ensure the health of the pub-
lic were defined in the National Academy of Science’s
Institute of Medicine (IOM) report on The Future of
Public Health (43):
· Assessment of health status, risks, and services
· Development of health policy
· Assurance of quality health services
Surveillance (assessment) is the sine qua non of
infectious disease prevention programs; however, for
surveillance to be effective it must be specific. Con-
sider, for example, surveillance of viral hepatitis.
Only after the various agents of viral hepatitis were
identified and specific laboratory testing became
available was it possible to explain trends in disease
prevalence and establish the epidemiologic princi-
ples underlying the different modes of transmission.
Specific laboratory testing is also the basis of screen-
ing programs that ensure the safety of the blood
supply against hepatitis B and hepatitis C. Agent-
specific surveillance is a critical component of many
immunization programs. Vaccines to Haemophilus
influenzae type b, (Hib), for example, were developed
in response to laboratory-based surveillance that
identified Hib as a major cause of invasive disease
in children. The effectiveness of the Hib vaccination
campaign in the United States has been dramatic
(Figure 1). Similar approaches will ensure appropri-
ate formulation of other developmental vaccines.
Monitoring antibiotic resistance is yet another im-
portant example of the value of laboratory-based
Table 1. Major Etiologic Agents, Infectious Diseases Identified Since 1973*
Year Agent   Disease      Reference
1973 Rotavirus Major cause of infantile diarrhea worldwide 19
1975 Parvovirus B19 Fifth disease; Aplastic crisis in chronic hemolytic
anemia
20
1976 Cryptosporidium parvum Acute enterocolitis 21
1977 Ebola virus Ebola hemorrhagic fever 22
1977 Legionella pneumophila Legionnaires’ disease 23
1977 Hantaan virus Hemorrhagic fever with renal syndrome (HFRS) 24
1977 Campylobacter sp. Enteric pathogens distributed globally 25
1980 Human T-cell lymphotropic
virus-I (HTLV I)
T-cell lymphoma—leukemia 26
1981 Staphylococcus toxin Toxic shock syndrome associated with tampon use 27
1982 Escherichia coli O157:H7 Hemorrhagic colitis; hemolytic uremic syndrome 28
1982 HTLV II Hairy cell leukemia 29
1982 Borrelia burgdorferi Lyme disease 30
1983 Human immunodeficiency virus
(HIV)
Acquired immunodeficiency syndrome (AIDS) 31
1983 Helicobacter pylori Gastric ulcers 32
1988 Human herpesvirus-6 (HHV-6) Roseola subitum 33
1989 Ehrlichia chaffeensis Human ehrlichiosis 34
1989 Hepatitis C Parenterally transmitted non-A, non-B hepatitis 35
1991 Guanarito virus Venezuelan hemorrhagic fever 36
1992 Vibrio cholerae O139 New strain associated with epidemic cholera 37
1992 Bartonella (= Rochalimaea)
henselae
Cat-scratch disease; bacillary angiomatosis 38, 39
1993 Hantavirus isolates Hantavirus pulmonary syndrome 40
1994 Sabiá virus Brazilian hemorrhagic fever 41
*Compiled by CDC staff. Dates of discovery are assigned on the basis of the year the isolation or identification of etiologic agents
was reported.
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ies of etiologic agents and diseases (Table 1) are
reasons for optimism. The potential for improve-
ments in assessment and prevention of these and
other newly discovered diseases is reminiscent of the
watershed years of Koch and Pasteur.
We cannot overstate the role of behavioral science
in our effort to “get ahead of the curve” with emerg-
ing infections. Having the science or laboratory tech-
nology to control infectious diseases is not enough,
unless we can influence people to behave in ways
that minimize the transmission of infections and
maximize the efforts of medical interventions. For
example, even though HIV/AIDS does not have a
vaccine or cure, it is almost entirely preventable. For
many people, however, reducing the risk for HIV
infection and AIDS requires important changes in
lifestyle or behavior. We must use our knowledge of
human behavior to help people make lifestyle
changes and prevent disease.
Another illustration of the need to use behavior
science is the problem of antibiotic resistance. To a
great extent, this problem is related to the behavior
of both physicians and patients. Physicians continue
to use antibiotics inappropriately, and patients con-
tinue to demand antibiotic treatment when it is not
indicated, for example, for the common cold. As soci-
ety changes and institutions such as day care centers
and prisons become more crowded, the spread of
infectious diseases is exacerbated. For homeless and
drug-dependent populations, completing a 6- to 9-
month course of therapy for tuberculosis is difficult,
and the failure to complete the therapy increases the
risk for drug-resistant tuberculosis in the commu-
nity.
Microbiologists, infectious disease specialists,
and other basic and clinical scientists must collabo-
rate with behavioral scientists in an interdiscipli-
nary effort to prevent and control emerging
infections.
The Future of Public Health emphasizes the rela-
tionship between a sound public health infrastruc-
ture and infectious disease prevention programs.
Infrastructure improvements must become a na-
tional priority: certainly they are among CDC’s top
priorities. Improvements in infectious disease sur-
veillance are particularly needed (44). Enriching the
capacity to respond to urgent threats to health and
developing nationwide prevention strategies are
also CDC priorities. To combat new and reemerging
infectious diseases, CDC, in collaboration with other
federal agencies, state and local health depart-
ments, academic institutions, professional societies,
international organizations, and experts in public
health infectious diseases and medical microbiology
developed a plan—Addressing Emerging Infectious
Disease Threats: A Prevention Strategy for the
United States (7). The plan has four major goals:
· Surveillance and Response—detect, promptly
investigate, and monitor emerging pathogens,
the diseases they cause, and the factors influenc-
ing their emergence
· Applied research—integrate laboratory sci-
ence and epidemiology to optimize public health
practice
· Prevention and control—enhance communi-
cation of public health information about emerg-
ing diseases and ensure prompt implementation
of prevention strategies
· Infrastructure—strengthen local, state, and
federal public health infrastructures to support
surveillance and implement prevention and con-
trol programs
CDC’s plan provides a framework for the agency
to work collaboratively with its many partners to
identify and reverse worrisome trends in infectious
diseases.
The need for implementing CDC’s plan is urgent,
given the extremely dynamic nature of disease
trends and the complexity of factors contributing to
disease emergence; these were outlined in detail in
the 1992 IOM report—Emerging Infections: Micro-
bial Threats to Health in the United States (45) and
are discussed in a companion article by Stephen S.
Morse, Ph.D., in this issue. The IOM report concludes
that infectious diseases must be viewed as but one
component of a dynamic and complex global ecology,
which is shaped and buffeted by technologic, socie-
tal, economic, environmental, and demographic
Figure 1. Race-adjusted incidence rate* of
Haemophilus influenzae type b and non-type b disease
detected through laboratory-based surveillance†
among children aged <5 years  —  United States,
1989–1993
*Per 100,000 children aged <5 years.
† The surveillance area population was 10.4 million in four
states (three counties in the San Francisco Bay Area, eight
counties in metropolitan Atlanta, four counties in Tennessee,
and the state of Oklahoma.
Source: CDC. Progress toward elimination of Haemophilus
influenzae type b disease among infants and children
— United States, MMWR 1994;43:144-8.
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tation.
Clearly, broader coalitions are needed, and com-
munication must improve if we are to “get ahead of
the curve.” This new periodical is part of the overall
strategy to draw worldwide attention to emerging
infections and improve communication. Given the
multiplicity of factors contributing to disease emer-
gence, Emerging Infectious Diseases (EID) will pre-
sent relevant concepts from professionals in
multiple disciplines and disseminate information
about emerging infectious diseases in order to de-
velop and apply ecologically acceptable interven-
tions that will benefit humankind. Prevention and
control of new and emerging infectious diseases de-
pend on the participation of scientists and other
professionals in the public and private sectors.
CDC will make EID available by print and elec-
tronically to facilitate rapid communication. We
hope that in the process EID will promote the ex-
change of infectious disease information through
global electronic networks and bulletin boards.
Although there are many similarities between
our vulnerability to infectious diseases and that of
our ancestors, there is one distinct difference: we
have the benefit of extensive scientific knowledge.
Ultimately, our success in combatting infectious dis-
eases will depend on how well we use available
information. A recent report by the Carnegie Com-
mission “Science, Technology, and Government for a
Changing World,” provides valuable insight in this
regard (46). Commenting on the Earth Summit in
Rio de Janeiro in 1992, the report emphasizes the
need to shift from the “manifestations of environ-
mental changes in the air, land, water, and plant and
animal kingdoms to the causes of those changes.”
Indeed, the advice of that report challenges us all—
"our capacity to generate, integrate, disseminate,
and apply knowledge will determine the human
prospect in the 21st century."
Dr. Satcher is director of the Centers for Disease
Control and Prevention, Atlanta, Georgia. He was
president of Meharry Medical College, Nashville,
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member of the King-Drew Medical Center and the
UCLA School of Medicine, Los Angeles, California.
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